MatrixCare vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Senior living and long-term care management software for skilled nursing, assisted living, and home health organizations. Minneapolis, MN. Acquired by ResMed.
About
MatrixCare is a Minneapolis, Minnesota-based provider of electronic health record and business management software for the senior living and post-acute care market. Acquired by ResMed (NYSE: RMD) in 2018, MatrixCare operates as ResMed's long-term care software division and serves over 15,000 care settings across skilled nursing facilities, senior living communities, home health agencies, and hospice providers. The platform provides EHR, billing, scheduling, and analytics capabilities designed for the clinical and operational complexity of long-term care.\n\nMatrixCare's product suite includes separate but integrated modules for skilled nursing, senior living (assisted living and memory care), home health, and hospice care, reflecting the different clinical workflows and regulatory requirements across these settings. The skilled nursing module addresses Medicare and Medicaid billing complexity, MDS documentation, and therapy management. The senior living module focuses on activity of daily living documentation, resident assessment tracking, and billing for private-pay and Medicaid waiver programs.\n\nResMed's acquisition of MatrixCare reflected the strategic importance of care coordination between home-based care (ResMed's core sleep therapy and respiratory device business) and facility-based post-acute care. The combined organization can offer integrated monitoring data from connected medical devices alongside clinical documentation in the EHR, positioning MatrixCare within ResMed's broader digital health strategy. MatrixCare competes directly with PointClickCare as the two dominant EHR platforms in the North American LTPAC market.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.